EvaluatePharma recently released its annual, World Preview 2015, Outlook to 2020, revealing that, like last year, partnered drugs make up the majority of the top 50 selling drugs worldwide.

At first glance, it appears that only 28 of the top 50 drugs are partnered products. However, when taking into account mergers and acquisitions and marketing partnerships, that number jumps to 39 of the top 50, making nearly 80% of the top 50 selling products in the world the result of partnering. Partnered drugs also boast higher average sales worldwide.

Gilles Toulemonde, Inova CEO, commented that, “The results of this study reinforce our belief that this is the age of the team – partnerships drive innovation and bring innovative products to market faster. We’re also proud to see that Inova’s clients continue to outperform the market, owning rights to over half of the top 50 drugs, including 7 of the top 10.”